Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis.

Trial Profile

Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Dec 2016

At a glance

  • Drugs Dasatinib (Primary) ; Zoledronic acid (Primary)
  • Indications Advanced breast cancer; Bone metastases
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Dec 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.
    • 10 May 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 08 Dec 2015 Planned End Date changed from 1 Mar 2016 to 1 Mar 2017, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top